Vktx nasdaq.

Viking Therapeutics, Inc. (NASDAQ:VKTX) insiders who bought shares over the past year were rewarded handsomely last week.The stock rose 8.7%, resulting in a US$167m rise in the company's market ...Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have received an average rating of “Buy” from the nine analysts that are presently covering the …During the last session, Viking Therapeutics Inc (NASDAQ:VKTX)’s traded shares were 1.77 million, with the beta value of the company hitting 0.59. At the end of the trading day, the stock’s price was $12.22, reflecting an intraday gain of 3.30% or $0.39. The 52-week high for the VKTX share is $25.72, that puts it down -110.47 from that peak ...Find the latest SEC Filings data for Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.

Find real-time VKTX - Viking Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.NASDAQ VKTX. Open. $12.01. Change. $0.69 (5.83%) Day's Range. $12.01 - $12.67. 52-Week Range. $3.54 - $25.72. Volume. 562.4K. Market Cap. $1.3B. Currency in USD. …

P/E & PEG Ratios. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a ...Viking Therapeutics, Inc. Common Stock (VKTX) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.

VKTX (U.S.: Nasdaq) Overview Profile FinancialsMarket Cap. $1.3B. Currency in USD. Quote data delayed by at least 15 minutes. Viking Therapeutics, Inc. Common Stock (VKTX) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets. Shares of the clinical-stage metabolic disorder specialist Viking Therapeutics ( VKTX -2.28%) were down by 6.45% on moderate volume as of 1:42 p.m. ET Thursday afternoon. The drugmaker's shares ...According to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2022 Results Conference Call February 8, 2023 4:30 AM ETCompany Participants. Stephanie Diaz - Investor Relations. Brian Lian - President and Chief ...

Apr 24, 2023 · Average portfolio weight of all funds dedicated to VKTX is 0.12%, an increase of 480.40%. Total shares owned by institutions increased in the last three months by 27.67% to 35,011K shares.

Find the latest Insider Activity data for Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com. Average portfolio weight of all funds dedicated to VKTX is 0.08%, an increase of 365.99%. Total shares owned by institutions increased in the last three months by 26.65% to 35,130K shares.NASDAQ: VKTX Viking Therapeutics. Market Cap. $1B. Today's Change (1.85%) $0.21. Current Price. $11.56. ... (VKTX 1.85%) are down about 25% from the peak they reached in mid-March. If you weren't ...In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price target of $35.00.The company’s shares opened ...Fiscal Q3 2023 ended 9/30/23. Reported on 10/25/23. Get the latest Viking Therapeutics Inc (VKTX) real-time quote, historical performance, charts, and other financial information to …

Dec 1, 2023 · Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock. SAN DIEGO , March 29, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic a... 8 months ago - PRNewsWire. VKTX Viking Therapeutics Options Ahead of Earnings Analyzing the options chain and the chart patterns of VKTX Viking Therapeutics prior to the earnings report this week, I would consider purchasing the 11usd strike price Calls with an expiration date of 2024-1-19, for a premium of approximately $1.80.May 18, 2023 · NASDAQ: VKTX Viking Therapeutics. Market Cap. $1B. Today's Change (-2.28%) -$0.28. ... (VKTX-2.28%) were down by 6.45% on moderate volume as of 1:42 p.m. ET Thursday afternoon. The drugmaker's ... seekingalpha.com - August 22 at 1:56 AM. Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Bought by Barclays PLC. marketbeat.com - August 15 at 5:09 AM. Viking Therapeutics stock gets boost from positive news that obesity drugs reduced risk of heart attacks and strokes. msn.com - August 9 at 6:40 PM.Dec 4, 2023 · Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have received an average rating of “Buy” from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. Nine analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have covered the stock in the […]

He does not neglect the obesity-centered candidate VK2735, however, and writes, “We view VKTX’s lead candidate THR-β agonist VK2809 for NASH as similar to …Shares of clinical-stage biotech Viking Therapeutics ( VKTX 6.68%) fell by as much as 4.8% on exceptionally low volume during the first hour of trading Tuesday morning. Since this mid-single-digit ...

Here's why they chose Bluebird Bio (NASDAQ: BLUE), Travere Therapeutics (NASDAQ: TVTX), and Viking Therapeutics (NASDAQ: VKTX). The upside is huge, but beware of the risks .Find the latest Earnings Report Date for Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.Viking Therapeutics (NASDAQ: VKTX) stock is on the move Wednesday as the clinical-stage biopharmaceutical company reveals data from a clinical trial. This data comes from its Phase 1 study of ...SVB Securities analyst Thomas Smith maintained a Buy rating on Viking Therapeutics (VKTX - Research Report) on October 26 and set a price target o... SVB Securities analyst Thomas Smith maintained a Buy rating on Viking Therapeutics (VKTX -...VKTX Nasdaq Stock Market • delayed by 15 minutes • CURRENCY IN USD • Biotechnology & Medical Research. VIKING THERAPEUTICS, INC. (VKTX) Compare. VIKING THERAPEUTICS, INC. 12.28 ...Viking Therapeutics, Inc. Common Stock (VKTX) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. Nasdaq Composite Stock Market Premium Services. Stock Advisor. Our Flagship Service. Return. ... VKTX. $12.01 (-2.24%) $0.28 *Average returns of all recommendations since inception. Cost basis and ...

Viking Therapeutics, Inc. (VKTX-NASDAQ) announced the presentation of data from a proof of concept a 35.7% mean reduction in liver weight. The company is On September 11, 2017, Viking announced positive results from clinical trial of patients with Current Price (09/12/17) $1.16 Valuation $7.00 OUTLOOK SUMMARY DATA Risk Level …

Viking Therapeutics Inc ( NASDAQ:VKTX) reported a strong quarter-end cash position of $376M. The company's net loss for Q3 2023 was $22.5 million, or $0.23 per share, compared to a net loss of $15 ...

Based on analysts offering 12 month price targets for VKTX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . According to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...Mar 16, 2023 · VKTX has move up from $4.00 a share to nearly $11.00 a share, largely in sympathy since those Madrigal trial results were announced. Therefore, I have taken profits on most of my small stake in VKTX. Since the year began, shares of Viking Therapeutics (NASDAQ:VKTX) exploded from about $8 to about $25 a share. All thanks to its potential treatment for obesity, VK2735. All thanks to its ...Viking Therapeutics last announced its quarterly earnings data on October 25th, 2023. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.01. Viking Therapeutics has generated ($0.93) earnings per share over the last year ( ($0.93) diluted earnings per share).Fintel reports that on May 16, 2023, Oppenheimer maintained coverage of Viking Therapeutics (NASDAQ:VKTX) with a Outperform recommendation.. Analyst Price Forecast Suggests 35.91% Upside. As of ...See the latest Viking Therapeutics Inc stock price (VKTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.See the latest Viking Therapeutics Inc stock price (VKTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Since the year began, shares of Viking Therapeutics (NASDAQ:VKTX) exploded from about $8 to about $25 a share. All thanks to its potential treatment for obesity, VK2735. All thanks to its ...Viking Therapeutics, Inc. Common Stock (VKTX) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.The latest price target for Viking Therapeutics (NASDAQ: VKTX) was reported by Truist Securities on Monday, October 2, 2023. The analyst firm set a price target ...Dec 4, 2023 · The public float for VKTX is 89.39M and currently, short sellers hold a 18.98% ratio of that float. The average trading volume of VKTX on December 04, 2023 was 2.05M shares. VKTX) stock’s latest price update. Viking Therapeutics Inc (NASDAQ: VKTX)’s stock price has plunge by 9.99relation to previous closing price of 13.01. Instagram:https://instagram. workhorse stock newsforex etf list6 month t billscedarfx About Institutional Holdings. Nasdaq provides the ownership stake information in a company, including the number of shares held by those institutions in a firm, along with recent purchases and ... Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. uber eats stockwebuy Find the latest Viking Therapeutics, Inc. (VKTX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. ... Nasdaq 14,305.03 +78.83 ... warrior traders Viking Therapeutics, Inc. (VKTX-NASDAQ) 7 b t z This model is highly dependent upon continued clinical k c Current Price (01/23/19) $8.11 Valuation $28.00 -OUTLOOK SUMMARY DATA Risk Level52 High Type of Stock Small-Value Industry Med-Biomed/Gene 5 P/E using 2018 Estimate P/E using 2019 Estimate We’ve recently heard from investors …Viking Therapeutics, Inc. (NASDAQ:VKTX) insiders who bought shares over the past year were rewarded handsomely last week.The stock rose 8.7%, resulting in a US$167m rise in the company's market ...Viking Therapeutics Inc. (VKTX) is an innovative biotechnology company developing novel therapeutics for metabolic and endocrine diseases. Metabolic and rare disease programs include novel selective thyroid... VKTX : 12.28 (+6.23%) Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire - Thu Sep 7, 3:05PM CDT.